The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

One of the most notable studies compared trastuzumab deruxtecan ... particularly interstitial lung disease and pneumonitis, which necessitates careful monitoring[1][3][5]. In a broader context ...

In the DATROWAY arm, the interstitial lung disease (ILD ... diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo ...

In the DATROWAY arm, the interstitial lung disease (ILD ... collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and DATROWAY in July 2020, except ...